Wall Street brokerages expect Nevro Corp (NYSE:NVRO) to post earnings per share of ($0.81) for the current quarter, Zacks Investment Research reports. Five analysts have issued estimates for Nevro’s earnings, with the highest EPS estimate coming in at ($0.47) and the lowest estimate coming in at ($0.97). Nevro reported earnings of ($0.37) per share in the same quarter last year, which would indicate a negative year over year growth rate of 118.9%. The firm is expected to report its next quarterly earnings report on Monday, November 4th.
According to Zacks, analysts expect that Nevro will report full year earnings of ($3.87) per share for the current financial year, with EPS estimates ranging from ($4.23) to ($3.36). For the next financial year, analysts anticipate that the company will post earnings of ($2.81) per share, with EPS estimates ranging from ($3.64) to ($1.35). Zacks Investment Research’s earnings per share calculations are an average based on a survey of research analysts that that provide coverage for Nevro.
Nevro (NYSE:NVRO) last issued its earnings results on Thursday, August 8th. The medical equipment provider reported ($0.91) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.89) by ($0.02). The firm had revenue of $93.60 million during the quarter, compared to the consensus estimate of $88.40 million. Nevro had a negative return on equity of 39.62% and a negative net margin of 24.51%. Nevro’s revenue for the quarter was down 2.6% on a year-over-year basis. During the same quarter in the prior year, the business earned ($0.35) earnings per share.
A number of equities research analysts recently commented on NVRO shares. JMP Securities increased their price target on Nevro from $70.00 to $90.00 and gave the company a “market outperform” rating in a research report on Monday. Zacks Investment Research raised Nevro from a “sell” rating to a “hold” rating and set a $67.00 target price for the company in a research report on Tuesday. ValuEngine raised Nevro from a “buy” rating to a “strong-buy” rating in a research report on Wednesday, July 24th. Canaccord Genuity raised their target price on Nevro from $50.00 to $59.00 and gave the company a “hold” rating in a research report on Friday. Finally, Morgan Stanley set a $76.00 target price on Nevro and gave the company a “buy” rating in a research report on Friday. Two equities research analysts have rated the stock with a sell rating, four have given a hold rating, five have assigned a buy rating and one has given a strong buy rating to the stock. The company currently has a consensus rating of “Hold” and a consensus price target of $62.91.
In other news, Director Kevin C. Oboyle purchased 1,675 shares of the business’s stock in a transaction dated Wednesday, June 5th. The stock was bought at an average price of $60.00 per share, for a total transaction of $100,500.00. The acquisition was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, Director Elizabeth H. Weatherman purchased 2,460 shares of the business’s stock in a transaction dated Friday, June 7th. The shares were purchased at an average price of $60.99 per share, with a total value of $150,035.40. The disclosure for this purchase can be found here. 7.60% of the stock is currently owned by corporate insiders.
Several hedge funds have recently bought and sold shares of NVRO. Advisor Group Inc. boosted its stake in Nevro by 64.5% in the 4th quarter. Advisor Group Inc. now owns 921 shares of the medical equipment provider’s stock worth $36,000 after purchasing an additional 361 shares during the period. Quantamental Technologies LLC bought a new position in Nevro in the 2nd quarter worth about $75,000. Prudential Financial Inc. bought a new position in Nevro in the 2nd quarter worth about $202,000. Redmile Group LLC bought a new position in Nevro in the 1st quarter worth about $213,000. Finally, Aperio Group LLC bought a new position in Nevro in the 2nd quarter worth about $227,000.
NYSE NVRO traded up $1.78 on Thursday, reaching $81.04. The company had a trading volume of 546,347 shares, compared to its average volume of 576,474. The stock has a market capitalization of $2.27 billion, a PE ratio of -49.41 and a beta of 0.29. The business has a fifty day moving average price of $64.86. Nevro has a 52-week low of $34.75 and a 52-week high of $81.13. The company has a quick ratio of 4.87, a current ratio of 6.30 and a debt-to-equity ratio of 0.83.
Nevro Company Profile
Nevro Corp., a medical device company, provides products for the patients suffering from chronic pain in the United States and internationally. The company develops and commercializes the Senza spinal cord stimulation system, an evidence-based neuromodulation platform for the treatment of chronic pain.
See Also: What is the balance sheet?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Nevro Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nevro and related companies with MarketBeat.com's FREE daily email newsletter.